Elite Pharmaceuticals, Inc. (ELTP)
0.2286
0.00 (0.00%)
USD |
OTCM |
Oct 02, 16:00
Elite Pharmaceuticals Enterprise Value : 212.92M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 212.92M |
| October 01, 2026 | 211.14M |
| September 30, 2026 | 227.08M |
| September 29, 2026 | 224.07M |
| September 28, 2026 | 237.42M |
| September 25, 2026 | 244.66M |
| September 24, 2026 | 232.45M |
| September 23, 2026 | 234.73M |
| September 22, 2026 | 232.63M |
| September 21, 2026 | 227.51M |
| September 18, 2026 | 233.22M |
| September 17, 2026 | 235.81M |
| September 16, 2026 | 230.53M |
| September 15, 2026 | 234.52M |
| September 14, 2026 | 246.47M |
| September 11, 2026 | 249.92M |
| September 10, 2026 | 237.10M |
| September 09, 2026 | 243.56M |
| September 08, 2026 | 246.58M |
| September 04, 2026 | 244.53M |
| September 03, 2026 | 247.87M |
| September 02, 2026 | 264.14M |
| September 01, 2026 | 273.29M |
| August 31, 2026 | 276.31M |
| August 28, 2026 | 277.76M |
| Date | Value |
|---|---|
| August 27, 2026 | 276.85M |
| August 26, 2026 | 273.62M |
| August 25, 2026 | 274.69M |
| August 24, 2026 | 278.03M |
| August 21, 2026 | 284.39M |
| August 20, 2026 | 287.03M |
| August 19, 2026 | 293.00M |
| August 18, 2026 | 293.54M |
| August 17, 2026 | 298.39M |
| August 14, 2026 | 300.54M |
| August 13, 2026 | 352.79M |
| August 12, 2026 | 354.40M |
| August 11, 2026 | 355.48M |
| August 10, 2026 | 354.51M |
| August 07, 2026 | 355.48M |
| August 06, 2026 | 351.92M |
| August 05, 2026 | 355.37M |
| August 04, 2026 | 359.68M |
| August 03, 2026 | 366.90M |
| July 31, 2026 | 374.76M |
| July 30, 2026 | 368.08M |
| July 29, 2026 | 366.90M |
| July 28, 2026 | 370.56M |
| July 27, 2026 | 381.33M |
| July 24, 2026 | 384.04M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Daré Bioscience, Inc. | 6.932M |
| Eton Pharmaceuticals, Inc. | 1.569B |
| ANI Pharmaceuticals, Inc. | 1.893B |
| Corcept Therapeutics, Inc. | 12.24B |
| Veru, Inc. | 19.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 5.911M |
| Revenue (Quarterly) | 32.36M |
| Total Expenses (Quarterly) | 26.44M |
| EPS Diluted (Quarterly) | 0.0052 |
| Gross Profit Margin (Quarterly) | 40.61% |
| Profit Margin (Quarterly) | 18.27% |
| Earnings Yield | 11.50% |
| Operating Earnings Yield | 13.95% |
| Normalized Earnings Yield | 3.542 |